SHERIDAN, WYOMING – May 6, 2025 – GE HealthCare (Nasdaq: GEHC) has reported a strong start to 2025 with notable revenue and profit gains in the first quarter, signaling resilience amid global trade complexities and bolstering its long-term value proposition through innovation and strategic acquisitions.
The company achieved a 3% year-over-year increase in total revenue to $4.8 billion, with organic revenue growth reaching 4%. Net income rose to $564 million from $374 million a year earlier, pushing the net income margin to 11.8%, up from 8.0%. Adjusted EBIT margin also improved slightly to 15.0%, reflecting strong operational execution and productivity improvements.
Strong Performance Across Key Financial Indicators
GE HealthCare’s Q1 2025 results demonstrate robust demand and improved profitability across its portfolio, particularly in the U.S. market. Total company orders rose a record 10% organically, yielding a book-to-bill ratio of 1.09—a clear sign of healthy backlog and continued commercial momentum.
Key highlights from the quarter include:
- Revenue: $4.8 billion, up 3% reported and 4% organically.
- Net Income: $564 million versus $374 million year-over-year.
- Net Income Margin: 11.8%, up 380 basis points.
- Adjusted EBIT: $715 million, with a 15.0% margin.
- Diluted EPS: $1.23, up from $0.81; Adjusted EPS: $1.01, up from $0.90.
- Cash Flow from Operations: $250 million, down from $419 million.
- Free Cash Flow: $98 million, down from $274 million.
Strategic Expansion and Market Resilience
GE HealthCare’s recent acquisition of Nihon Medi-Physics marks a strategic move to expand access to its next-generation radiopharmaceuticals, a critical step in advancing precision care. The company continues to invest in its growth acceleration strategy, targeting areas of high market demand and clinical innovation.
“First quarter results reflect strong execution as we start the year with robust revenue, orders and profit growth, which were driven by strength in the U.S.,” said Peter Arduini, GE HealthCare President and CEO. “We remain focused on delivering on our precision care and growth acceleration strategies, underscored by the closing of our acquisition of Nihon Medi-Physics, which we expect will increase global access to our next-generation radiopharmaceuticals.”
Arduini added, “We continue to see strong customer demand in many of the markets we serve and are well-positioned to drive long-term value as we invest in future innovation.”
Shareholder Confidence Reinforced with Buyback Authorization
In a move reflecting continued confidence in the company’s trajectory and financial strength, GE HealthCare’s Board of Directors authorized a $1 billion share repurchase program. This decision highlights a commitment to returning value to shareholders while maintaining investment in innovation and operational scalability.
Navigating Trade Headwinds and Positioning for Growth
Despite the complexities of the current global trade environment, GE HealthCare is actively implementing mitigation strategies. The company remains focused on balancing short-term pressures with long-term priorities, including advancing its precision care model, enhancing digital solutions, and expanding global reach.
As healthcare providers worldwide demand more integrated, data-driven, and patient-centric solutions, GE HealthCare’s ongoing investments in radiopharmaceuticals and precision diagnostics align with evolving industry needs and regulatory trends.
To stay updated on GE HealthCare’s financial performance and strategic developments, learn more at www.gehealthcare.com.